|
November 21, 2023
|
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
|
|
|
November 21, 2023
|
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
|
|
|
November 20, 2023
|
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
|
|
|
September 12, 2023
|
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
|
|
|
September 12, 2023
|
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
|
|
|
August 24, 2023
|
Connect Biopharma to Participate in Upcoming September Investor Conferences
|
|
|
July 10, 2023
|
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
|
|
|
July 5, 2023
|
Connect Biopharma to Participate in the SVB Securities Therapeutics Forum
|
|
|
June 1, 2023
|
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
|
|
|
April 11, 2023
|
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
|
|
